- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05835895
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis (DONATELLO)
March 29, 2024 updated by: Genascence Corporation
A Phase 1b, Randomized, Double-Blinded, Placebo-Controlled Dose Ranging Study to Evaluate Safety, Tolerability and Pharmacodynamics of a Single Intra-articular Injection of GNSC-001 Gene Therapy in Subjects With Osteoarthritis of the Knee
The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001) is safe and tolerated compared to placebo in participants with painful osteoarthritis (OA) of the knee.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
65
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36608
- Recruiting
- Alliance for Medical Research Mobile
-
Contact:
- Missy MacPhail
- Phone Number: 816-721-0720
- Email: missy.macphail@amrllc.com
-
Principal Investigator:
- Russel Hudgens, MD
-
-
California
-
La Mesa, California, United States, 91942
- Recruiting
- Biosolutions Clinical Research Center
-
Contact:
- David Campos-Ruiz
- Phone Number: 619-637-0770
- Email: david@biosolutionsresearch.com
-
Principal Investigator:
- Pete Hanson, MD
-
San Diego, California, United States, 92037
- Recruiting
- UC San Diego
-
Contact:
- Thuy Pham
- Phone Number: 858-249-3015
- Email: ntp001@health.ucsd.edu
-
Principal Investigator:
- Susan Bukata, MD
-
-
Florida
-
Miami, Florida, United States, 33173
- Recruiting
- Well Pharma Medical Research
-
Principal Investigator:
- Eddie Armas, MD
-
Contact:
- Michelle De La Cruz
- Phone Number: 305-665-4818
- Email: mdelacruz@wpharma.com
-
Miami Springs, Florida, United States, 33166
- Recruiting
- South Florida Research
-
Contact:
- Lisbelle Revoredo
- Phone Number: 305-418-0847
- Email: lrevoredo@southfloridatrials.com
-
Principal Investigator:
- Belkis Delgado, MD
-
The Villages, Florida, United States, 32159
- Recruiting
- Premier Medical Associates
-
Principal Investigator:
- Sanjay Shah, MD
-
Contact:
- Paige Deckard
- Phone Number: 352-446-9585
- Email: pdeckard@vantagetrials.com
-
-
Illinois
-
Oak Brook, Illinois, United States, 60523
- Recruiting
- Affinity Health
-
Contact:
- Tasin Hameed
- Phone Number: 640-451-9627
- Email: tasin.hameed@amrllc.com
-
Principal Investigator:
- Sana Meah, DO
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- Recruiting
- Alliance for Multispecialty Research Kansas City
-
Contact:
- Missy MacPhail
- Phone Number: 816-721-0720
- Email: missy.macphail@amrllc.com
-
Principal Investigator:
- Sue Fanning, MD
-
-
North Carolina
-
Morehead City, North Carolina, United States, 28557
- Recruiting
- West Clinical Research
-
Principal Investigator:
- Jeffrey Moore, MD
-
Contact:
- Luke Snedaker
- Phone Number: 252-515-0050
- Email: Info@westclinicalresearch.com
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Recruiting
- Altoona Center For Clinical Research
-
Contact:
- Ellen Rosen
- Phone Number: 188 814-693-0300
- Email: ellenrosen@altoonaresearch.com
-
Principal Investigator:
- Alan Kivitz, MD, CPI
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- OA in at least one knee (the 'target knee'), confirmed using centrally read X-ray with a Kellgren-Lawrence (KL) score of 2 or 3
- Western Ontario & McMaster University Osteoarthritis Index (WOMAC) pain score ≥ 20 (on a 50-point numerical rating scale) in the target knee during the seven days prior to Screening
- Persistent moderate to severe symptoms in the target knee, despite failure or intolerance of a 3-month trial of at least 2 conservative therapies (e.g., activity modification, weight loss, physical therapy, opioids, and anti-inflammatory medications, and injection of hyaluronic acid or steroids)
- Successful extraction of synovial fluid at Screening
- Negative pregnancy test at Screening and Baseline (subjects of childbearing potential [SOCBP])
Key Exclusion Criteria:
- Current or documented history of inflammatory arthritis (such as gout or rheumatoid arthritis), inflammation of connective tissue, or other immunological disease
- Any form of joint degeneration as part of another syndrome (e.g., Ehler's Danlos, Stickler syndrome, etc.)
- Surgery in the target knee within the 6 months prior to screening
- Previous partial or total joint replacement in target knee
- Significant and clinically evident malalignment of the target knee that would impact the subject's function, as determined by the Investigator
- Body mass index (BMI) > 38 kg/m2
- Clinically significant abnormal laboratory values at Screening in laboratory parameters that in the opinion of the Investigator, could represent a potential risk to participant safety:
- Plans to have, elective surgery of other joints or spine or intra-articular injections in the target knee, within the next 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
intra-articular injection
|
Experimental: GNSC-001 (low dose)
|
intra-articular injection
Other Names:
|
Experimental: GNSC-001 (high dose)
|
intra-articular injection
Other Names:
|
Experimental: GNSC-001 (low dose) + transient immune-modulation (oral)
|
intra-articular injection
Other Names:
oral
intra-articular injection
|
Experimental: GNSC-001 (high dose) + transient immune-modulation (oral)
|
intra-articular injection
Other Names:
oral
intra-articular injection
|
Experimental: GNSC-001 (high dose) + transient immune-modulation (oral + injectable)
|
intra-articular injection
Other Names:
oral
intra-articular injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time Frame: Month 12
|
Month 12
|
Severity of TEAEs and SAEs
Time Frame: Month 12
|
Month 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in synovial Interleukin-1 Receptor Antagonist (IL-1Ra) levels over time, from Baseline
Time Frame: Baseline to Month 1, 3, 6, 12, and 24
|
Baseline to Month 1, 3, 6, 12, and 24
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Immunogenicity of a single dose of GNSC-001
Time Frame: Month 6 and 12
|
Month 6 and 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Lachy McLean, MD, Genascence Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 12, 2023
Primary Completion (Estimated)
May 1, 2025
Study Completion (Estimated)
May 1, 2029
Study Registration Dates
First Submitted
April 19, 2023
First Submitted That Met QC Criteria
April 19, 2023
First Posted (Actual)
April 28, 2023
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
March 29, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CPRO-22-001
- CLIN2-14265 (Other Grant/Funding Number: California Institute for Regenerative Medicine)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Novartis PharmaceuticalsRecruitingSymptomatic Knee OsteoarthritisUnited States, Spain, Hungary, Argentina, Germany, Slovakia, Czechia, Belgium, Romania
-
University of BathUniversity of Oxford; 3D Metal Printing Ltd; Versus ArthritisRecruitingMedial Knee OsteoarthritisUnited Kingdom
-
Max Biocare Pty. Ltd.Completed
Clinical Trials on GNSC-001
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Heartseed Inc.RecruitingHeart Failure | Ischemic Heart DiseaseJapan
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Astrogen, Inc.RecruitingAutism Spectrum DisorderKorea, Republic of
-
StimuSILAnkara City Hospital Bilkent; Istanbul University - Cerrahpasa (IUC)RecruitingAndrogenetic Alopecia | Hair Loss | Male Pattern Baldness | Hair Loss/Baldness | Pattern BaldnessTurkey
-
MediciNovaCompletedInterstitial CystitisUnited States